ALASCCA is a randomized, parallel group, double blind, multicenter, placebo-controlled,
biomarker-based study of adjuvant treatment with low dose aspirin in patients with colorectal
cancer. Hypothesis is that patients diagnosed with colorectal cancer and somatic mutations in
PI3K pathway can significantly improve survival if treated with low dose aspirin.
Phase:
Phase 3
Details
Lead Sponsor:
Anna Martling
Collaborators:
Skane University Hospital Uppsala University Hospital